Elanco Animal Health Incorporated Common Stock

5 analysts have expressed a variety of opinions on Elanco Animal Health (NYSE:ELAN) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 1 0 1 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 1 0 0 3M Ago 0 2 0 0 1 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $18.2, a high estimate of $23.00, and a low estimate of $14.00. This upward trend is evident, with the current average reflecting a 17.42% increase from the previous average price target of $15.50. Understanding Analyst Ratings: A Comprehensive Breakdown In examining recent analyst actions, we gain insights into how financial experts perceive Elanco Animal Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Balaji Prasad Barclays Raises Overweight $23.00 $19.00 David Westenberg Piper Sandler Raises Neutral $18.00 $12.00 Nathan Rich Goldman Sachs Raises Sell $14.00 $12.50 Erin Wright Morgan Stanley Raises Overweight $17.00 $16.00 Balaji Prasad Barclays Raises Overweight $19.00 $18.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Elanco Animal Health. This information provides ...Full story available on Benzinga.com

Related tickers: ELAN.

Elanco Animal Health Incorporated (NYSE:ELAN) reported first-quarter adjusted EPS of $0.34, down 26% year over year, beating the consensus of $0.26 and management guidance of $0.25-$0.28. The animal health company’s sales of $1.21 billion were down 4% year over year, beating the consensus of $1.174 billion and guidance of $1.16 billion—$1.185 billion. The ERP Blackout negatively impacted growth by an estimated 7% to 9%. Pet Health revenue was $639 million, down 5% year over year, with a 3% increase in price compared to the first quarter of 2023. Farm Animal revenue was $556 million, down 3%.  Guidance: Elanco Animal Health forecasts 2024 adjusted EPS of $0.88-$0.96 versus prior guidance of ...Full story available on Benzinga.com

Related tickers: ELAN.